Completed NA INTERVENTIONAL 1-arm NCT00856700

Glucagon-like Peptide 1 (GLP-1) and Endothelial Dysfunction in Metabolic Syndrome

Effect of GLP-1 on Endothelial Function and Glucose Uptake in Patients With Metabolic Syndrome

Sponsor: Merck Sharp & Dohme LLC

Updated 6 times since 2017 Last updated: Dec 10, 2013 Started: Nov 30, 2008 Primary completion: Jun 30, 2012 Completion: Jun 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00856700, this NA trial focuses on Metabolic Syndrome and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 6 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jun 2022 — Jul 2024 [monthly]

Completed NA
Jan 2021 — Jun 2022 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC
University of Rome Tor Vergata

Data source: University of Rome Tor Vergata

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rome, Italy